Special purpose acquisition corporations did not have a very successful run in the last SPAC wave to hit the life science sector, but a new round of the vehicles that provide companies an alternative means of going public has emerged recently. Even before the market for initial public offerings has fully recovered, private biopharmaceutical firms may now consider merging with a SPAC rather than going public through an IPO.
Finance Watch: SPACs Attempt A Comeback Ahead Of Full IPO Recovery
Many Go-Public Alternatives Performed Badly Previously
Public Company Edition: Several special purpose acquisition corporations have emerged, including various health care- and life science-focused SPACs. Also, Alvotech entered into a $965m refinancing agreement and Avidity grossed $461m in a follow-on offering, among other updates.
